Trevi Therapeutics Makes Strides with Haduvio for Chronic Cough
Trevi Therapeutics, Inc. is making headlines as it has reported impressive topline results from its Phase 2a RIVER trial. This study evaluates Haduvio (oral nalbuphine ER), a potential breakthrough in the treatment for patients suffering from chronic cough, involving a diverse group of 66 individuals.
Significant Findings from the RIVER Trial
The results reveal that Haduvio met its primary endpoint, showcasing a statistically significant reduction in 24-hour cough frequency. Patients experienced a 67% reduction from their baseline and a noteworthy 57% when adjusted for placebo. This finding is compelling for both researchers and patients alike.
Further analysis demonstrates significant effects on specific subgroups. In patients suffering from severe cough, defined as those experiencing more than 20 coughs per hour, there was a remarkable 66% reduction. Similarly, the moderate cough subgroup benefited, showing a 68% reduction, underscoring Haduvio’s effectiveness across various intensities of chronic cough.
Patient Outcomes and Safety Profile
When considering patient-reported outcomes, the results were equally promising. About 84% of patients taking Haduvio reported at least a 30% reduction in their cough frequency, compared to just 29% in the placebo group—a significant difference that highlights the potential impact of the treatment.
Importantly, the trial's safety results aligned with Haduvio’s previously established profile. The most common adverse effects included constipation, nausea, headache, and fatigue, but there were no serious treatment-related adverse events reported, ensuring a degree of reassurance regarding the drug’s safety in a clinical setting.
Timeline for Future Trials
Looking ahead, Trevi Therapeutics is already advancing its research. In February, the company completed enrollment for its Phase 2b CORAL trial, which further tests Haduvio for chronic cough in patients with idiopathic pulmonary fibrosis. Topline results from this study are anticipated within the first half of the upcoming year, which could illuminate the treatment's effectiveness in a different patient demographic.
Current Market Reaction
Following the announcement of these promising results, TRVI stock saw a significant jump, appreciating by 40.2%, with the last check landing at $6.03. This reflection of investor confidence illustrates the market’s positive reception of Trevi Therapeutics’ progress in treating chronic cough.
Frequently Asked Questions
What is Haduvio?
Haduvio is an oral formulation of nalbuphine ER developed by Trevi Therapeutics for treating chronic cough.
What were the results of the Phase 2a RIVER trial?
The trial demonstrated a 67% reduction in cough frequency for those taking Haduvio compared to baseline.
What percentage of patients showed improvement?
84% of patients treated with Haduvio reported at least a 30% reduction in their cough frequency.
Is Haduvio considered safe?
Yes, the safety profile of Haduvio is consistent with prior studies, showing no serious adverse treatment-related events.
What is the next step for Trevi Therapeutics?
The next significant step is the Phase 2b CORAL trial results, expected in the first half of next year.
